TipRanks
Corbus Pharmaceuticals (DE:3371)
FRANKFURT:3371
Germany Market

Corbus Pharmaceuticals (3371) Drug Pipeline

0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Cetuximab, Docetaxel, Crb-701, Capcitabine
Oropharyngeal Carcinoma (Opc)
Phase III
Not Yet Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Aug 12, 2026
―
Crb-913
Obese But Otherwise Healthy Participants
Phase I
Active Not Recruiting
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
Dec 16, 2025
Crb-601 Monoclonal Antibody, Anti-Pd-1 Monoclonal Antibody
Solid Tumor
Phase I/II
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Sep 13, 2024
Crb-701, Anti-Pd-1
Solid Tumor, Adult
Phase I/II
Recruiting
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Feb 08, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Corbus Pharmaceuticals (3371) have in its pipeline
      3371 is currently developing the following drugs: Cetuximab, Docetaxel, Crb-701, Capcitabine, Crb-913, Crb-601 Monoclonal Antibody, Anti-Pd-1 Monoclonal Antibody. These drug candidates are in various stages of clinical development as the company works toward FDA approval.